



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 541 551 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)
INID code(s) 74

(48) Corrigendum issued on:
09.11.2005 Bulletin 2005/45

(43) Date of publication:
15.06.2005 Bulletin 2005/24

(21) Application number: **03741499.2**

(22) Date of filing: **18.07.2003**

(51) Int Cl.7: **C07D 207/16**, C07D 401/12,
C07D 401/14, C07D 403/12,
C07D 405/12, C07D 451/04,
A61K 31/4025, A61K 31/4155,
A61K 31/439, A61K 31/454,
A61K 31/4545, A61K 31/5377,
A61K 31/541, A61P 3/10,
A61P 43/00, C07D 409/12

(86) International application number:
PCT/JP2003/009179

(87) International publication number:
WO 2004/009544 (29.01.2004 Gazette 2004/05)

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR
Designated Extension States:
AL LT LV MK

(30) Priority: **23.07.2002 JP 2002213654**
10.09.2002 JP 2002264450

(71) Applicant: **Astellas Pharma Inc.**
Chuo-ku, Tokyo (JP)

(72) Inventors:
• **HAYAKAWA, Masahiko**
c/o Yamanouchi Pharmaceut. Co.
Tsukuba-shi, Ibaraki 305-8585 (JP)
• **NEGORO, Kenji**
c/o Yamanouchi Pharmaceutical Co.Ltd
Tsukuba-shi, Ibaraki 305-8585 (JP)

- **MIYAMOTO, Satoshi**
c/o Yamanouchi Pharmaceutical Co
Tsukuba-shi, Ibaraki 305-8585 (JP)
- **SUZUKI, Takayuki**
c/o Yamanouchi Pharmaceutical Co.
Tsukuba-shi, Ibaraki 305-8585 (JP)
- **MARUYAMA, Tatsuya**
c/o Yamanouchi Pharmaceutical Co
Tsukuba-shi, Ibaraki 305-8585 (JP)
- **NAKANO, Ryosuke**
c/o Yamanouchi Pharmaceutical Co.
Tsukuba-shi, Ibaraki 305-8585 (JP)

(74) Representative: **HOFFMANN EITLE**
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München (DE)

(54) **2-CYANO-4-FLUOROPYRROLIDINE DERIVATIVE OR ITS SALT**

(57) Provided is a compound having excellent dipeptidyl peptidase IV-inhibiting activity, and a remedy based on the activity for insulin-dependent diabetes (type 1 diabetes), especially for non insulin-dependent diabetes (type 2 diabetes), insulin-resistant disorders, and obesity.

EP 1 541 551 A8